jRCT1041190082招募中不适用
Phase II study of sorafenib-regorafneib sequential therapy for the patients with advanced hepatocellular carcinoma previously treated with lenvatinib
未提供0 个研究点目标入组 33 人开始时间: 2019年12月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 33
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; good liver functional reserve; 20 years old or older, ECOG Performance status <=2; preservation of major organ function; written informed consent
排除标准
- •refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; unstable angina or myocardial infarction; severe complication; active infection; pregnant or lactating women and her partner, or women of childbearing potential; mental disorder; other factors unsuitable for participant
结局指标
主要结局
-
1-year survival rate
次要结局
未报告次要终点
研究者
相似试验
招募中
2 期
Phase II study of sorafenib-regorafneib sequential therapy for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190082Yamashita Tatsuya33
已完成
2 期
Phase II study of sorafenib with S-1 for advanced hepatocellular carcinoma.Hepatocellular carcinomaJPRN-UMIN000007199Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University25
进行中（未招募）
1 期
A randomized phase II trial assessing Sorafenib (Nexavar®) in combination with irinotecan in metastatic colorectal cancer patients with KRAS mutated tumours after failure of all active drugs known to be effective. - NEXIRI 2metastatic colorectal cancerMedDRA version: 16.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2012-000644-94-FRCentre Val d’Aurelle - Paul Lamarque159
进行中（未招募）
1 期
A Phase 2 study of Sorafenib (BAY 43-9006) in patients with advanced salivary Adenoid Cystic CarcinomaEUCTR2008-000066-22-GBChristie Hospital NHS Foundation Trust
已完成
2 期
Phase II trial of Sorafenib combined with on-demand Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer stage C)JPRN-UMIN000014213Clinical Research Group of the Japanese Society for Transcatheter Hepatic Arterial Embolization32